Improved immunoradiometric assay for plasma renin by Deinum, J. (Jacob) et al.
Improved Immunoradiometric Assay for
Plasma Renin
Jaap Deinum,* Frans H.M. Derkx, and Maarten A.D.H. Schalekamp
Background: Our renin IRMA overestimated renin in
plasmas with high prorenin-to-renin ratios. We sus-
pected that the overestimation of renin was caused less
by cross-reactivity of the renin-specific antibody with
prorenin than by a conformational change of prorenin
into an enzymatically active form during the assay.
Methods: Because the inactive form of prorenin con-
verts slowly into an active form at low temperature, we
raised the assay temperature from 22 °C to 37 °C, simul-
taneously shortening the incubation time from 24 to 6 h.
The former IRMA was performed in <1 working day
with these modifications.
Results: The comeasurement of prorenin as renin was
eliminated. Reagents were stable at 37 °C, and the new
and old IRMAs were comparable in terms of precision
and accuracy. The functional lower limit of the assay (4
mU/L) was below the lower reference limit (9 mU/L).
The modified IRMA agreed closely with the activities
measured with an enzyme-kinetic assay. Results were
not influenced by the plasma concentration of angio-
tensinogen. At normal angiotensinogen concentrations,
the IRMA closely correlated with the classical enzyme-
kinetic assay of plasma renin activity.
Conclusion: The modified IRMA, performed at 37 °C,
avoids interference by prorenin while retaining the
desirable analytical characteristics of the older IRMA
and requiring less time.
© 1999 American Association for Clinical Chemistry
The aspartic protease renin is rate-determining in the pro-
teolytic cascade that leads to generation of angiotensin (Ang)
II,1 a key factor in the regulation of blood pressure and the
maintenance of water and salt homeostasis (1). Renin is
produced exclusively in the kidney from its enzymatically
inactive precursor, prorenin. Prorenin is produced not only
in the kidney, but also in other organs, such as the adrenal
gland (2), the ovary (3), the testis (4), and the uteroplacental
unit (5). Its secretion into the blood is continuous, in contrast
to the tightly controlled release of renin. The concentration
of prorenin in nondiseased plasma is approximately nine-
fold higher than that of renin and is much less subject to
short-term fluctuations than renin (6).
Enzyme-kinetic measurements of the so-called plasma
renin activity (PRA) are often used to assess the in vivo
activity of the renin-angiotensin system, rather than the
difficult and labor-intensive measurement of Ang II. In
the PRA assay, plasma is incubated at 37 °C. During this
incubation, renin acts on an endogenous renin substrate,
angiotensinogen, to generate Ang I. The degradation of
Ang I and its conversion to Ang II are blocked by protease
inhibitors that have been added to the plasma. The Ang I
generated in vitro is quantified by radioimmunoassay.
Because angiotensinogen circulates at a concentration
roughly equal to the Km, the rate of Ang I generation in
the PRA assay depends as much on the concentration of
renin as on that of angiotensinogen. Plasma angiotensino-
gen concentrations may vary; therefore, PRA is not al-
ways a good measure of renin release by the kidney. To
overcome this problem, exogenous angiotensinogen can
be added to the incubation mixture at a saturating con-
centration. This is the principle of the enzyme-kinetic
plasma renin concentration (PRC) assay.
Recently, our group described the clinical validation of
an IRMA for plasma renin (7 ). This assay measures renin
directly, is better to standardize, and is less labor-inten-
sive than the classical enzyme-kinetic PRA and PRC
assays. Our report, however, sparked a polemic on the
specificity of the new assay (8–10) because in the IRMA
some prorenin is measured as renin, and therefore, the
reliability of the assay at low renin concentrations might
be insufficient. We therefore set out to improve our
method to minimize the comeasurement of prorenin.
We hypothesized that the problem was caused less by
cross-reactivity of the renin-specific antibody with native,
enzymatically inactive prorenin than by inadvertent acti-
vation of prorenin during the assay procedure. It is
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known that prorenin spontaneously undergoes a confor-
mational change by which it becomes enzymatically ac-
tive (active prorenin). This change does not require the
proteolytic cleavage of the prosegment and does not
necessarily lead to generation of renin. The nonproteolytic
activation of prorenin is time- and temperature-depen-
dent. Activation occurs mainly at low temperature (4 °C)
(11 ). Our original IRMA was performed at room temper-
ature. Spontaneous activation of prorenin over time has
been detected at room temperature, but is virtually absent
at 37 °C (12 ). We therefore attempted to prevent the
inadvertent activation of prorenin by shortening the in-
cubation time of the assay and raising the incubation
temperature to 37 °C.
Materials and Methods
antibodies
The monoclonal antibodies (mAbs) R3-36-16 and R1-20-5
against renin and prorenin were purchased in a kit from
Nichols Diagnostics. Briefly, the primary mAb, R3-36-16,
is a biotinylated monoclonal mouse anti-human antibody
that binds renin as well as active and inactive prorenin.
The secondary mAb, R1-20-5, is radio-iodinated (125I) and
binds only renin and active prorenin. Detailed informa-
tion on the antibodies is given in Ref. (13 ). mAb F258-
37-B1 was provided by Dr. S. Mathews (Hoffmann-La
Roche, Basle, Switzerland) and was elicited against the
C-terminal portion of the propeptide of prorenin. The
epitope of this region of the propeptide is hidden in
native, enzymatically inactive prorenin, but is expressed
on the active form of prorenin (14 ). Like mAb R3-36-16,
mAb F258-37-B1 was biotinylated (15 ).
avidin-coated plastic beads, washing buffer, and
sheep serum
Biotinylated bovine serum albumin was coupled to 8-mm
diameter polystyrene beads (Precision Plastic Balls), after
which the beads were coated with avidin (15 ) and stored
at 4 °C. The washing buffer, phosphate-buffered saline
containing 0.1 mL/L Triton X-100, was provided by
Nichols Diagnostics. Serum from healthy sheep was heat
inactivated for 1 h at 56 °C.
renin calibrators
Recombinant human renin was provided by Nichols
Diagnostics. We calibrated this renin preparation against
the WHO human kidney renin standard, International
Reference Preparation (IRP), lot no. 68/356 (National
Institute for Biologic Standards and Control, Potters Bar,
Hertfordshire, UK) (16 ) in the enzyme-kinetic PRC assay
(see below). Serial dilutions of human recombinant renin
to be used for constructing the calibration curve were
made up in undiluted sheep serum. The sheep serum
content of the renin calibrators was, therefore, near 100%,
contrary to what was stated in our previous report (7 ) on
a renin IRMA. The dilutions of the renin calibrators were
then lyophilized and stored at 4 °C. Before assay, the
lyophilisates were reconstituted in distilled water.
renin inhibitor
Remikiren, an active site-directed renin inhibitor, was
obtained from Hoffmann-La Roche (17 ). Remikiren is a
nonpeptide transition-state analog with a Mr of 726. The
IC50 for purified human renin is 0.7 3 10
29 mol/L, and
the Ki for the reaction with human renin is 3 3 10
210
mol/L (17 ). Only freshly prepared solutions of remikiren
were used.
angiotensinogen
Angiotensinogen was prepared from the plasma of ne-
phrectomized sheep (18 ). The partially purified prepara-
tion was dialyzed against 0.15 mol/L phosphate-buffered
saline, pH 7.4, and neomycin sulfate was added (final
concentration, 2 g/L). The final preparation had an an-
giotensinogen concentration of 1.2 3 1026 mol/L, deter-
mined as described below.
nonproteolytic activation of prorenin
Prorenin was treated with the renin inhibitor remikiren to
change the molecular conformation from an inactive form
into a form that is recognized by the mAb specific for
renin (19 ). We refer to this remikiren-induced conforma-
tional change of prorenin as “activation”, despite the fact
that the prorenin-remikiren complex lacks enzymatic ac-
tivity. To activate all the prorenin in plasma, we added 1
volume of remikiren (1023 mol/L) to 10 volumes of
plasma and incubated the mixture for 24 h at 4 °C (19 ).
assays
Enzyme-kinetic assays of renin. To measure PRC, we used
our in-house assay, as described previously (20, 21). In
short, we added 250-mL aliquots of sheep angiotensino-
gen solution to 25- to 250-mL aliquots of plasma and
adjusted the volume to 500 mL with 0.15 mol/L phos-
phate-buffered saline, pH 7.4, and added 17.5 mL of a
protease inhibitor solution consisting of two volumes of
0.34 mol/L 8-hydroxyquinoline sulfate, one volume of
0.287 mol/L phenylmethylsulfonyl fluoride in ethanol,
two volumes of 0.5 mol/L disodium EDTA, and two
volumes of aprotinin (10 000 kallikrein-inhibiting units/
mL). We incubated the mixture at 37 °C for at least two
different time periods between 0.25 and 3 h to verify
linear Ang I generation. The final concentration of sheep
angiotensinogen in the incubation mixture was 6 3 1027
mol/L (Km, 2 3 10
27 mol/L). Only incubations in which
,5% of the angiotensinogen was hydrolyzed were ac-
cepted for calculating the concentration of naturally oc-
curring renin. Parallel incubations at 0 °C served as
blanks. The generated Ang I was measured by RIA (22 ).
Results of the PRC measurements were expressed as
mU/L, as calibrated with the international renin stan-
dard. Under the conditions of the assay, 1 mU of renin
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generated 163 pmol (212 ng) of Ang I per hour. The lower
limit of detection was 1 mU/L.
For the PRA assay, we used a modification of the
method proposed by Sealey (23 ). The method was mod-
ified to include blank subtraction, and the 18-h incubation
for low renin samples was eliminated. In this assay, 50 mL
of maleic acid, pH 5.7, and 12.5 mL of a protease inhibitor
solution consisting of one volume of 0.287 mol/L phenyl-
methylsulfonyl fluoride in ethanol, two volumes of 0.5
mol/L disodium EDTA, and two volumes of 100 g/L
neomycin sulfate were added to 0.5 mL of plasma. The
mixture was then incubated at 37 °C for at least two time
periods between 0.5 and 3 h to check for linear generation
of Ang I. The generated Ang I was quantified by RIA (22 ).
Results were expressed as nmol Ang I/L per hour. The
lower limit of detection was 0.08 nmol Ang I/L per hour.
Assay of angiotensinogen. The concentration of angio-
tensinogen in plasma was determined as the maximal
quantity of Ang I that was generated during incubation at
pH 7.4 and 37 °C of plasma to which recombinant human
renin had been added at a final activity of 20 000 mU/L.
The results were expressed as nmol/L (21 ).
IRMAs. To 200-mL aliquots of untreated plasma,
remikiren-treated plasma, or renin calibrators, we added
100 mL of a 1:1 mixture, by volume, of biotinylated mAb
R3-36-16 (0.5 mg/L) and radiolabeled [;250 000 counts
per minute (cpm)] mAb R1-20-5. We incubated this mix-
ture with a polystyrene, avidin-coated bead in duplicate
for either 24 h at room temperature (IRMA 22 °C, 24 h) or
for 6 h at 37 °C (IRMA 37 °C, 6 h). After incubation, we
washed the beads three times and then transferred the
washed beads to clean tubes. The radioactivity of the
bound antibody was counted for 5 min in a gamma
counter. The assay measures renin in the untreated plas-
mas and renin plus prorenin in the remikiren-treated
plasmas. The difference between the results of the two
measurements was the prorenin.
To test our hypothesis that comeasurement of prorenin
as renin was caused by a conformational change in the
prorenin, we also performed another, two-step sandwich
assay. This assay was a modification of an assay we
described earlier (14 ) and measured prorenin directly
after remikiren activation. In this assay, an avidin-coated
bead carrying 1 mg of biotinylated F258-37-B1 was incu-
bated for 6 h at 37 °C or for 24 h at 22 °C with plasma from
a patient with high plasma prorenin (prorenin, 2757
mU/L; renin, 53.1 mU/L). The F258-37-B1-coated bead
bound the exposed propeptide of the active form of
prorenin (14 ), but did not bind renin or native, inactive
prorenin. The half-time of binding of active prorenin to
the bead at 37 °C was ;12 min. After incubation, we
rinsed the bead three times with 2 mL of phosphate-
buffered saline containing 1 g/L bovine serum albumin to
remove all renin and inactive prorenin. We then incu-
bated the bead with sheep serum containing remikiren
(1024 mol/L) and radiolabeled R1-20-5 for 24 h at 22 °C.
The tracer antibody bound the active prorenin trapped on
the bead. We added remikiren in this second step to
ensure that any active prorenin captured on the bead in
the first step was kept in its active conformation. After
incubation, we washed the beads with 3 3 2 mL of
washing buffer and counted bound radioactivity after the
bead was transferred to a clean tube. A standard line of
remikiren-treated recombinant human prorenin in sheep
serum was used (14 ). The lower limit of detection of
this assay was ;10 mU/L active prorenin. The inter-
assay CV at ,100 mU/L active prorenin was ;10%.
collection of plasma samples
Plasma samples were from healthy subjects, patients with
essential hypertension either not receiving therapy or receiv-
ing enalapril, patients with renovascular hypertension either
not receiving therapy or receiving enalapril, patients with
hepatic cirrhosis, and patients with primary aldosteronism
(Conn syndrome). Individuals with conditions where a high
prorenin-to-renin ratio is not unusual, i.e., pregnant women,
women with ovarian hyperstimulation, women with pre-
eclampsia, women taking oral contraceptives, and patients
with diabetes mellitus, were also studied. Blood sampling
was performed according to our in-house protocol. Blood
samples were collected from subjects after cannulation of an
antecubital vein and 30–45 min of supine rest. The samples
were collected into tubes containing 0.2 mL of 0.646 mol/L
citrate per 10 mL of blood and centrifuged immediately at
room temperature. The plasma was stored at 220 °C.
Shortly before each assay, plasma samples were thawed
rapidly and kept at room temperature.
Results
performance characteristics of the renin
irma at 37 8c
Calibration curve. Fig. 1 depicts a comparison of the
calibration curve of IRMA 37 °C, 6 h with the calibration
curves of IRMA 37 °C, 24 h and IRMA 22 °C, 24 h. The
results, expressed as cpm, were linear over a wide range
of renin concentrations. IRMA 37 °C, 24 h and IRMA
22 °C, 24 h produced identical results. It appears, there-
fore, that the reagents were stable at 37 °C. The calibration
curve of IRMA 37 °C, 6 h was parallel to those of the 24-h
IRMAs, but the values were 25% lower. This difference was
fully explained by the first-order rate constant for the bind-
ing of the radiolabeled mAb to renin at 37 °C (0.23 h21; data
not shown). For practical purposes, we chose IRMA 37 °C,
6 h instead of IRMA 37 °C, 24 h as our routine assay,
although the quantity of radiolabeled mAb trapped by renin
was somewhat lower after 6 h than after 24 h.
We tested the linearity of the assay by preparing
dilutions of plasma samples with 5.7–2106 mU/L renin.
Dilutions were made up in the same matrix, i.e., sheep
serum, that was used for the calibration curve. Plots of the
results, expressed as mU/L, against the dilution factor
gave straight lines with the correct slope (Fig. 2).
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Analytical recovery. The human kidney renin IRP was
added to plasma samples containing 7.4–155 mU/L renin.
As shown in Table 1, IRMA 37 °C, 6 h demonstrates
excellent analytical recovery of both low and high quan-
tities of added renin. The mAbs we used are capable of
inhibiting the Ang I-generating activity of renin (13 ). To
investigate whether angiotensinogen might interfere with
the binding of renin to these antibodies, we added the
human kidney renin IRP to a plasma obtained from a
pregnant woman. This plasma (plasma D in Table 1) had
an angiotensinogen concentration of 3208 nmol/L, which
is approximately threefold higher than the reference
value. Angiotensinogen at this high concentration did not
influence the results of IRMA 37 °C, 6 h (see Table 1).
Assay imprecision and detection limits. As shown in Fig. 1,
the detection limit of IRMA 37 °C, 6 h, defined as 3 SD
above the zero calibrator, was 1.3 mU/L. The radioactiv-
ity of the zero calibrator of this calibration curve was
;150 cpm, and that of the 4 mU/L calibrator was ;300
cpm. Thus, the result for the calibrator was close to the
blank. This raised concern about the reliability of the
IRMA renin measurements at the lower end of the con-
centration range. This issue is addressed in Fig. 3, which
shows the results, expressed as cpm, for 4 mU/L human
recombinant renin and for nonspecific binding (blank) in
32 individual assays. Fig. 3 shows adequate separation
between the 4 mU/L calibrator and the blank in each of
Fig. 1. Calibration curves for the IRMAs.
Ordinate, total binding of labeled antibody. Abscissa, renin activity. The shaded
area represents the reference interval. Inset, low range of the calibration curve
for IRMA 37 °C, 6 h (mean 6 3 SD).
Fig. 2. Plasma dilution tests for plasmas from a patient with renal
artery stenosis treated with enalapril (), a patient with untreated renal
artery stenosis (F), a pregnant woman (M), a patient with low-renin
hypertension (), and a patient with Conn syndrome (f).
Ordinate, results obtained with IRMA 37 °C, 6 h. The shaded area represents the
reference interval.
Table 1. Recovery of human kidney renin added to plasma.
Plasma
Renin added,
mU/L
Renin
concentration
before addition of
renin, mU/L
Renin
concentration
after addition of
renin, mU/L
Recovery of
added renin,
%
A 10 7.4 17.1 97
B 20 10.1 30.2 102
C 50 24.5 75.6 102
D 50 25.1 75.6 101
E 50 28.1 80.1 107
F 10 37.0 46.5 95
G 20 42.3 61.9 98
H 70 53.1 115.4 89
H 130 53.1 203.9 116
I 130 155 265.5 85
I 260 155 446 110
Fig. 3. Difference between the blank (nonspecific binding) and 4 mU/L
renin calibrator in all assays (IRMA 37 °C, 6 h) performed from January
1, 1998, to September 1, 1998.
Ordinate, radioactivity bound to the bead. The mean (6 SD) nonspecific binding
is shown on the left; the mean (6 SD) binding of the 4 mU/L calibrator is shown
on the right.
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the 32 assays. The variability of the duplicate blanks or the
duplicate 4 mU/L calibrators was low. The difference
between the duplicate blanks, given as median (range),
was 13.5 cpm (1–38 cpm), or 11% (1–35%) of the mean
blank (n 5 32). The difference between the duplicate 4
mU/L calibrators was 14 cpm (1–32 cpm), or 6% (0–15%)
of specific binding.
The intra- and interassay CVs for IRMA 37 °C, 6 h;
IRMA 22 °C, 24 h; and the enzyme-kinetic PRC assay at
low, medium, and high renin activities in plasma are
compared in Table 2. The intraassay CVs were similar for
the three assays. The interassay CVs for the plasmas with
low renin activity were, however, higher for the IRMAs
than for the enzyme-kinetic PRC assay. The “functional
sensitivity”, i.e., the minimum renin activity that could be
measured from assay to assay with ,20% CV, was ;4
mU/L (see Table 2).
comeasurement of prorenin
The results for a plasma pool from healthy subjects
measured with IRMA 37 °C, 6 h; IRMA 22 °C, 24 h; and
the enzyme-kinetic PRC assay are compared in Table 3.
The renin activity in the plasma pool measured with
IRMA 37 °C, 6 h was equal to that measured with the
enzyme-kinetic PRC assay and was ;25% lower than
the activity measured with IRMA 22 °C, 24 h. In contrast,
the results obtained with IRMA 37 °C, 6 h and with the
enzyme-kinetic PRC assay in a dilution of the human
kidney renin IRP in sheep serum were not different from
the results obtained with IRMA 22 °C, 24 h. This is an
indication that prorenin interferes with the measurement
of renin in IRMA 22 °C, 24 h. To further demonstrate that
a conformational change in prorenin at 22 °C is the source
of renin overestimation, we also used a two-step IRMA (at
22 and 37 °C) that measures the active conformation of
prorenin. When the first step of the assay incubation was
performed at 37 °C for 6 h, very little active prorenin was
measured in the second step (18 mU/L, ,1% of total
prorenin and close to the detection limit of the assay). In
contrast, when the same plasma was incubated with the
same beads at 22 °C for 24 h, the active prorenin measured
in the second step was 149 mU/L, i.e., 5.4% of total
prorenin. This indicates that in the course of incubation,
prorenin is activated and then captured by the F258-37-
B1-coated bead at 22 °C, but not at 37 °C. The results were
the same when the assay was repeated with the same
plasma, and similar results were observed for three other
plasmas with high prorenin. Activation of prorenin at
22 °C, but not at 37 °C, also explains the results presented
in Fig. 4, in which we compare the results obtained with
IRMA 22 °C, 24 h and IRMA 37 °C, 6 h with the results
obtained with the enzyme-kinetic PRC assay for plasmas
having different prorenin-to-renin ratios. Overestimation
of renin was frequent in IRMA 22 °C, 24 h, and was most
pronounced at high prorenin-to-renin ratios (Fig. 4, left-
hand plot). Overestimation of renin was not seen in IRMA
37 °C, 6 h. Fig. 5 shows a Bland-Altman plot comparing
IRMA 37 °C, 6 h with the enzyme-kinetic PRC assay.
Because the renin activity ranged over three orders of
magnitude and the differences were proportional to the
activity, the mean of the two assays was log-transformed
and the difference was corrected for the renin activity. The
plot demonstrates the good agreement between IRMA
37 °C, 6 h and the enzyme-kinetic PRC assay for the entire
range of renin activity in plasma.
In Table 4, the results presented in Figs. 4 and 5 are
grouped according to diagnostic categories. Table 4 also
compares the three types of renin measurement (IRMA
22 °C, 24 h; IRMA 37 °C, 6 h; and enzyme-kinetic PRC
assay) with the measurement of PRA in different patient
groups. The percentage of overestimation that was seen in
IRMA 22 °C, 24 h was most pronounced in patients with
diabetes mellitus, in pregnant women with or without
preeclampsia, and in gonadotropin-treated women. These
were the patient groups with the highest prorenin-to-
renin ratio. IRMA 22 °C, 24 h did not overestimate renin
in patients with renovascular hypertension treated with
enalapril and patients with liver cirrhosis. In these patient
groups, the prorenin-to-renin ratio was abnormally low.
Table 2. Intra- and interassay CVs determined in plasma samples.
Renin,a mU/L
Intrassay CV, %
n 5 6
Interassay CV, %
n 5 10
IRMA 22 °C,
24 h
IRMA
37 °C, 6 h
Enzyme-kinetic
PRC assay
IRMA 22 °C,
24 h
IRMA
37 °C, 6 h
Enzyme-kinetic
PRC assay
3.6 11 9.5 8.2 25 21 14
7.3 5.9 7.6 6.2 13 16 9.6
34.3 4.9 3.9 3.6 6.6 5.2 5.1
154 3.9 3.8 3.7 5.7 5.3 4.6
a Measured with enzyme-kinetic PRC assay.
Table 3. Renin concentrationa determined in a pool of
human plasma and in a dilution of human kidney renin in
sheep serum.
IRMA 22 °C, 24 h,
mU/L
IRMA 37 °C, 6 h,
mU/L
Enzyme-kinetic
PRC assay, mU/L
Plasma pool 30.6 6 3.6 24.5 6 1.5 25.1 6 1.6
Kidney renin 50.2 6 2.9 51.1 6 2.8 50.0 6 1.5
a Values are means 6 SD, n 5 3. Plasma samples from eight healthy subjects
were pooled; the prorenin concentration of this pool was 238 6 13 mU/L (IRMA
37 °C, 6 h).
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Many laboratories measure PRA instead of renin con-
centration. The results of the PRA assay are determined
not only by the concentration of renin, but also by the
concentration of angiotensinogen in plasma. We com-
pared the results obtained with IRMA 37 °C, 6 h with
those obtained with the PRA assay. Fig. 6 shows the
results for healthy subjects, for patients with untreated
essential hypertension, and for patients with Conn syn-
drome. The angiotensinogen concentration in these
plasma was normal, and the renin was normal or low. The
results of the PRA assay (with nmol Ang I z L21 z h21 as the
units) were 0.07 times the values found with the IRMA 37
°C, 6 h (with mU/L as the units). A similar correlation
was seen in other patient groups having normal renin and
angiotensinogen concentrations in their plasma (see Table
4). As expected, the PRA-to-IRMA ratio was higher in
patients with abnormally high angiotensinogen, and the
ratio was lower in patients with abnormally low angio-
tensinogen.
Discussion
The original IRMA for renin that we described previously
was not 100% specific for renin (7 ). It also measured a
small fraction (0.5–2%) of prorenin. Measurements in
plasma therefore led to an overestimation of renin. In
healthy subjects and in patients with essential or renovas-
cular hypertension, renin was overestimated by 20% or
less, but the deviation can be larger in situations in which
plasma prorenin comprises .90% of total renin, such as in
low-renin essential hypertension, pregnant women, in
patients with Conn syndrome, and in patients with dia-
betes mellitus.
The present study demonstrates that this problem is
solved in the improved assay. The tertiary structure of
renin and prorenin has the form of two lobes separated by
a cleft that contains the enzyme’s active site (24, 25). In
enzymatically inactive intact prorenin, the propeptide is
folded in this cleft, and angiotensinogen cannot reach the
active site. This so-called closed form of prorenin is in
dynamic equilibrium with an open form in which the
propeptide, although still covalently linked with the renin
portion of the molecule, has been displaced from the cleft,
and angiotensinogen can now reach the active site (14 ).
The transition of the closed form into the open, active
form takes hours, and the equilibrium is shifted toward
Fig. 4. Comparison of IRMA 22 °C,
24 h (IRMA 22; left) and IRMA 37 °C,
6 h (IRMA 37; right) with the enzyme-
kinetic PRC assay (EKA).
Ordinate, difference between each IRMA
and the enzyme-kinetic PRC assay, ex-
pressed as a percentage of the enzyme-
kinetic PRC assay. Abscissa, prorenin-to-
renin ratio as measured with IRMA 37 °C,
6 h. The slopes of the regression lines for
IRMA 22 and IRMA 37 (not depicted) are 41
and 5.9 (P ,0.001 and not significant,
respectively, for comparison with slope 5
0). The y-intercept is 27.2 for IRMA 22 and
23.7 for IRMA 37. The x-variable is log[pro-
renin-to-renin ratio]. The rightmost outlier
was omitted from analysis.
Fig. 5. Bland-Altman plot comparing
IRMA 37 °C, 6 h (IRMA 37) with the
enzyme-kinetic PRC assay (EKA).
Ordinate, difference between IRMA and the
enzyme-kinetic PRC assay, expressed as a
percentage of the renin activity (mean re-
nin 5 mean of IRMA and EKA). Abscissa,
mean of IRMA and enzyme-kinetic PRC as-
say. The mean of the difference between
IRMA 37 °C, 6 h and the enzyme-kinetic
PRC assay is 0.4%; SD 5 17%; n 5 121.
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the open form by lower temperatures (cryoactivation)
(12 ) or by the addition of active site-directed renin inhib-
itors (19 ). Our results, especially those of the two-step
IRMA that captures active prorenin, demonstrate that the
comeasurement of prorenin we observed in the original
IRMA 22 °C, 24 h, is caused by the formation of open
prorenin. This problem is almost completely overcome in
IRMA 37 °C, 6 h.
IRMAs usually are performed at room temperature. One
may therefore wonder whether the reagents we used are
stable at 37 °C. Our observation that the calibration curves
for IRMA 37 °C, 24 h and IRMA 22 °C, 24 h were identical
strongly suggests that the reagents are stable at 37 °C.
The renin calibrator was diluted in sheep serum to
minimize nonspecific binding of the mAbs. Theoretically,
the binding characteristics in the sheep serum matrix
might be different from those in human plasma. The
recovery of renin calibrator added to human plasma was
close to 100%, and serial dilutions of human plasma
produced decrements of binding that were linearly corre-
lated with the dilution factor. The close agreement be-
tween the results of IRMA 37 °C, 6 h with those of the
enzyme-kinetic PRC assay also indicates that the differ-
ence in the reaction milieu between plasma samples and
calibrators did not affect the results.
For plasma samples with normal or increased renin,
IRMA 37 °C, 6 h was as precise as the enzyme-kinetic PRC
assay (interassay CV ,10%). For plasma samples with
low renin activity (,10 mU/L), the precision of IRMA
37 °C, 6 h was less than that of the enzyme-kinetic PRC
assay. The functional sensitivity, defined as the minimum
activity that could be measured from assay to assay with
,20% CV, was ;4.0 mU/L. Our results show this to be
sufficient for measuring renin in plasmas from patients
with suppressed renin, such as patients with Conn syn-
drome or low-renin essential hypertension.
Many laboratories still use the enzyme-kinetic PRA
assay. From our results, it appears that the patients who
were diagnosed as having a low plasma renin activity on
the basis of results obtained with IRMA 37 °C, 6 h also
had abnormally low PRA.
The improved IRMA is specific for renin and appears
Table 4. Plasma renin, renin plus prorenin, angiotensinogen, and PRA in healthy subjects and in various groups of patients.
Subject group n
Renina Renin plus prorenina
IRMA 22 °C,
24 h, mU/L
IRMA 37 °C,
6 h, mU/L
Enzyme-
kinetic PRC
assay, mU/L
IRMA 22 °C,
24 h, mU/L
IRMA 37 °C,
6 h, mU/L
PRA, nmol
Ang I z L21 z
h21
Angiotensinogen,
nmol/L
PRA-to-renin
ratio
Controls 10 29.7b,c 24.9 23.3 198 202 2.01 918 0.079
15.9–62.2 14.6–38.9 10.2–36.2 131–347 123–344 1.15–6.09 823–1003 0.064–0.118
Essential hypertensives
No treatment 20 11.0b,c 9.1 8.5 139 138 0.58 1159 0.073
6.7–21.9 5.4–16.1 5.0–16.9 49–527 48–486 0.19–1.58 729–1628 0.029–0.114
Enalapril 9 38b,c 30.9 32.7 346 330 2.42 876 0.077
20.7–73.3 17.8–58.0 13.2–68.2 213–559 219–470 1.06–5.97 627–1189 0.029–0.114
Renovascular hypertension
No treatment 8 100.2b,c 86.3 94.7 426 411 7.43 1334 0.079
73.3–158 58–140 68.1–149 346–475 385–445 5.97–9.00 1189–1628 0.061–0.093
Enalapril 9 527 496 533 1233 1171 31.9 804 0.060d
153–1392 128–1188 124–1238 405–2034 383–1923 11.8–78.1 526–1139 0.038–0.095
Hyperaldosteronism (Conn
syndrome)
2 4.4, 9.4 4.1, 6.4 3.4, 5.4 44.0, 64.1 43.7, 68.2 0.33, 0.57 1105, 1244 0.081, 0.080
Liver cirrhosis 12 1892 1847 1777 NDf 3569 27.73 252d 0.015e
525–6821 528–7436 456–6830 807–4605 13.53–70.61 115–626 0.007–0.040
Diabetes mellitus (insulin-
dependent)
8 61.6b,c
45.4–82.4
36.8
24.4–54.4
38.3
25.0–57.5
691
381–904
678
381–859
3.28
1.79–7.08
903
784–1025
0.076
0.061–0.117
Pregnancy 10 67.7b,c 52.5 56.2 648 658 9.62 3535d 0.157e
33.7–127 29.6–121 30.7–147 367–1609 426–1348 5.35–20.8 2631–4675 0.065–0.210
Preeclampsia 9 27.3b,c 18.5 19.8 484 485 2.83 2501d 0.113e
7.6–56.3 5.4–40.4 4.2–44.0 139–1137 129–1137 1.09–4.93 1723–3711 0.064–0.189
Gonadotropin-treated
women
12 47.2b,c
19.9–110
27.9
14.0–57.8
27.2
12.4–56.7
ND 914
355–2345
3.31
1.54–7.64
2707d
1563–3981
0.122e
0.076–0.161
Women on oral
contraceptives
10 18.7b,c
12.1–36.8
16.9
11.0–34
15.9
9.2–33.0
122
95–152
130
101–135
2.01
0.85–4.68
2884d
1390–6776
0.133e
0.092–0.187
a Values are means and 95% confidence intervals.
b Significantly different from IRMA, 37 °C, 6 h: P ,0.01.
c Significantly different from enzyme-kinetic PRC assay: P ,0.01.
d,e Significantly different from control subjects: dP ,0.05; eP ,0.01.
f ND, not determined.
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to be a simple, precise, and accurate method for measure-
ments in clinical plasma samples. This assay is easier to
standardize than the enzyme-kinetic assays that rely on
endogenous angiotensinogen, such as the PRA assay. The
results obtained with the improved IRMA are expressed
in terms of the internationally recognized human renin
standard and, therefore, permit ready comparison be-
tween different laboratories.
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Fig. 6. Comparison of results obtained with IRMA 37 °C, 6 h with
results obtained with the enzyme-kinetic PRA assay for patients with
Conn syndrome (), patients with essential hypertension (F), and
control subjects (E).
The regression line was obtained by least-squares regression analysis after
logarithmic transformation of the results. The y-intercept (given as the antilog) is
0.056; the slope is 1.097; n 5 65. The shaded area represents the reference
interval.
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